FDA approves first PI3K inhibitor for breast cancer
On May 24, the FDA approved Piqray (alpelisib) tablets, to be used in combination with fulvestrant, to treat postmenopausal women, and men, with hormone…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.